Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis by Kumar Gubbala et al.
Gubbala et al. Journal of Ovarian Research 2014, 7:69
http://www.ovarianresearch.com/content/7/1/69RESEARCH Open AccessOutcomes of ovarian transposition in
gynaecological cancers; a systematic review
and meta-analysis
Kumar Gubbala1†, Alex Laios2*†, Ioannis Gallos3, Pubudu Pathiraja2, Krishnayan Haldar2 and Thomas Ind1Abstract
Background: Pelvic irradiation is essential for improving survival in women with pelvic malignancies despite
inducing permanent ovarian damage. Ovarian transposition can be performed in premenopausal women in an
attempt to preserve ovarian function. As uncertainty occurs over the proportion of women who are likely to benefit
from the procedure, we performed a systematic review and meta-analysis of the proportion of women with ovarian
function preservation, symptomatic or asymptomatic ovarian cysts and metastatic ovarian malignancy following
ovarian transposition.
Methods: Medline, Embase and The Cochrane Library databases were systematically searched for articles published
from January 1980 to December 2013. We computed the summary proportions for ovarian function preservation,
ovarian cyst formation and metastatic ovarian disease following ovarian transposition by random effects meta-analysis
with meta-regression to explore for heterogeneity by type of radiotherapy.
Results: Twenty four articles reporting on 892 women undergoing ovarian transposition were included. In the surgery
alone group, the proportion of women with preserved ovarian function was 90% (95% CI 92–99), 87% (95% CI 79–97)
of women did not develop ovarian cysts and 100% (95% CI 90–111) did not suffer metastases to the transposed
ovaries. In the brachytherapy (BR) ± surgery group, the proportion of women with preserved ovarian function was 94%
(95% CI 79–111), 84% (95% CI 70–101) of women did not develop ovarian cysts and 100% (95% CI 85–118) did not
suffer metastases to the transposed ovaries. In the external beam radiotherapy (EBRT) + surgery ± BR group, the
proportion of women with preserved ovarian function was 65% (95% CI 56–74), 95% (95% CI 85–106) of women did
not develop ovarian cysts and 100% (95% CI 90–112) did not suffer metastases to the transposed ovaries. Subgroup
meta-analysis revealed transposition to the subcutaneous tissue being associated with higher ovarian cyst formation
rate compared to the “traditional” transposition.
Conclusion: Ovarian transposition is associated with significant preservation of ovarian function and negligible risk for
metastases to the transposed ovaries despite common incidence of ovarian cysts.Introduction
Ovarian transposition (OT) has proven invaluable for
ovarian function preservation in patients with pelvic ma-
lignancies requiring pelvic irradiation. First described in
1958 [1], it was initially performed at laparotomy until
more recently when laparoscopic and robotic techniques
have been described [2,3]. Surgical approaches include* Correspondence: alex.laios@obs-gyn.ox.ac.uk
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the psoas muscle, the paracolic gutters, percutaneous
needle transposition of the ovaries and exteriorisation to
the subcutaneous fat tissue [4-8].
It has now been established as a simple and reliable
method with reduced morbidity [9]. Standard criteria for
the preservation and transposition of the ovaries have
been proposed [10]. In effect, the procedure is limited to
a population of young premenopausal patients with
early-stage, operable cervical tumours with a need for
primary or adjuvant radiotherapy. It can be additionally
performed for ovarian dysgerminomas, vaginal cancersl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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momas, Hodgkin’s disease, sarcomas and rectal carcin-
omas [11-13].
Ovulation induction and oocyte retrieval can be suc-
cessfully performed on transposed ovaries [14]. Studies
on OT have rendered rather conflicting results, particu-
larly those including patients who never went on to have
radiotherapy. Nonetheless, retained ovaries carry a risk
for symptomatic ovarian cysts and metastases to the
ovaries from the primary site [15]. Yet, significant uncer-
tainty exists regarding the efficacy of this procedure
from observational studies with small sample sizes,
which makes it difficult to counsel women accordingly.
To ascertain the efficacy of OT, we conducted a system-
atic review and meta-analysis of the proportion of
women who underwent OT with ovarian function pres-
ervation, symptomatic or asymptomatic ovarian cysts
and metastatic ovarian malignancy.
Materials and methods
Study Identification
The population of interest in this review included pre-
menopausal women with a diagnosis of a gynaecological
malignancy who might require radiotherapy in addition
to surgery. Patients who had OT without the need for
adjuvant radiotherapy and who underwent unilateral OT
were also included.
The intervention was OT and the outcomes included
ovarian function preservation, metastatic ovarian malig-
nancy and symptomatic or asymptomatic ovarian cysts.
MEDLINE, EMBASE and The Cochrane Library were
searched for articles published between January 1980
and April 2014. We used the following search strategy
combining text and Medical Subject and Emtree Head-
ings terms: women OR female AND ovar* transposition’
OR oophoropexy AND ovarian preservation OR ovarian
function OR premature ovarian failure OR ovarian cysts
OR metastases. No language restrictions were applied.
Studies of women who had gynaecological surgery for
benign indications resulting in ovarian cessation were
not included in the review. References of selected studies
were searched for articles not identified by the electronic
searches, in an attempt to find additional citations. Re-
view articles were not screened for additional citations.
Case reports or series with fewer than 3 cases were
excluded.
Study selection and data extraction
The following information were extracted; publication
date, type of study, duration of follow up, type of OT, re-
tention of ovarian function, incidence of metastasis,
ovarian cysts formation and associated complications.
Studies were selected in a 2-stage process. Firstly, titles
and abstracts from the electronic searches were screenedby 2 independent reviewers (KG and TI) and full manu-
scripts of all citations that met the predefined selection
criteria were obtained. Subsequently these articles were
evaluated in full text for each of the 3 objectives to make
the final selection. In case of duplicates, the most recent
or complete publication was selected. Any disagreements
were resolved by consensus or arbitration by a third
reviewer (AL). Summary (aggregate) outcome data ex-
tracted from each study were created in 2×2 tables (AL).
Preservation of ovarian function was assessed by patient's
symptoms and serum FSH, LH, E2 levels. Only patients
for which follow up was available were included in
the meta-analysis. The Methodological Index for Non-
Randomized Studies (MINORS), which assesses the qual-
ity of the included studies, was implemented [16]. For
reporting of results, we followed the recommendations of
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) [17].Statistical analysis
For the analysis of outcomes, we calculated the propor-
tions of women who had their ovarian function pre-
served, had no ovarian cysts and no metastases in the
transposed ovaries per total number of women undergo-
ing OT. We computed the logarithm of the ratio and its
corresponding standard error for each of the studies. A
meta-analysis with inverse-variance weighting was per-
formed using a random effects model. Forest plots were
created for each outcome showing individual study pro-
portions with confidence intervals (CIs) and the overall
pool estimate. Heterogeneity was statistically evaluated
using the I2 test. For funnel-plot asymmetry, we per-
formed the Egger’s weighted regression test. Statistical
analyses were performed using Stata 12.0 (Stata Corp,
College Station, TX).Results
The electronic search strategy initially yielded 396 cita-
tions. The selection process for included articles is
shown in Figure 1. We retrieved 26 articles for full text
examination and we further excluded a review article
[18] and an article with unrelated population as it was
not referring to gynaecological malignancy [19]. As a re-
sult, 24 primary studies, reporting on 892 women who
underwent OT were included in this review. The main
study characteristics are shown in Table 1. The quality
assessment of the studies in the MINORS checklist is
shown in Figure 2. All studies were observational. In
brief, 7/24 (29.1%) of studies were prospective including
consecutive patients in 21/24 (87.5%). There was an ad-
equate definition of outcomes in 20/24 (83.3%) studies.
No studies had a blinded assessment of the outcomes or
performed a prospective calculation of sample size. The
Figure 1 Study selection process.
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(79.1%) of studies.
In the majority of the studies, the procedure was per-
formed in patients less than 40 years of age. Surgery was
by laparotomy or laparoscopy. In 2 studies the ovaries
were transposed to the subcutaneous tissue [8,23]. The
vast majority of patients (n = 828) had cervical cancer;
43 patients had vaginal cancer, 10 patients had ovarian
dysgerminomas and 7 patients had pelvic sarcomas.
There were 4 cases of pelvic lymphomas.
Women included in the analysis had a diagnosis of can-
cer and their ovaries transposed. A total of 428 women
had surgery alone in the form of radical hysterectomy
(RH) ± pelvic lymphadenectomy (PLND) ± upper vaginect-
omy ± paraaortic lymph node dissection (PALND) (Group
A). 143 had post-operative brachytherapy (BR) (Group B).
321 had post-operative external beam radiotherapy
(EBRT) ± BR (Group C). The follow up ranged from 2 to
126 months (Table 1).
Preserved ovarian function
Pooling of results from 18 studies (n = 428 women) that
reported ovarian function as an outcome in group A
rendered a summary proportion of 90% (95% CI 82–99)
for ovarian function preservation with no significant
variation across the studies (I2 = 0.0%, p = 0.9) (Figure 3).
The summary proportion from 9 studies (n = 143 women)
for ovarian function preservation was also 90% (95% CI
79–111) for group B with no statistical variation across
the studies (I2 = 0.0%, p = 1) (Figure 4). Pooling of results
from 23 studies (n = 321 women) in group C rendered a
summary proportion of 65% (95% CI 56–74) for ovarian
function preservation with no significant variation across
the studies (I2 = 13.5, p = 0.27) (Figure 5). For the outcome
of ovarian function preservation no statistical significance
for small study effects and plot asymmetry was found
(Figure 6).Non metastases to the transposed ovaries
Pooling of results from 18 studies in group A, 10 studies
in group B and 23 studies in group C reported no me-
tastases to the transposed ovaries (95% CIs 90–111, 85–
118 and 90–112 for groups A, B and C respectively). No
significant variation across the studies for the 3 groups was
observed (I2 = 0.0%, p = 1). In absolute numbers, only 1
study reported 2 recurrences in group A. These 2 patients
had adenoid cystic carcinoma and cervical adenocarcinoma
respectively. They underwent surgery for recurrent cancer
19 and 27 months after primary RH and both had dissemi-
nated disease involving transposed ovaries.
No ovarian cyst formation
Pooling of results from 18 studies that reported no ovar-
ian cyst formation as an outcome in group A rendered a
summary proportion of 87% for no ovarian cyst forma-
tion (95% CI 79–97). There was significant variation
across the studies (I2 = 51.9%, p = 0.006). Interestingly,
subgroup meta-analysis revealed that women undergoing
subcutaneous OT (n = 2 studies, weight = 6.61%) had a
57% rate of no cyst formation compared to 90% on those
(n = 16 studies, weight = 93.4%) undergoing “traditional”
lateral OT (95% CI 38–85) versus (95% CI 81–100).
However, variation across the studies for both subgroups
was significant (I2 = 51.9%, p = 0.006) versus (I2 = 40.7%,
p = 0.046) (Figure 7).
The summary proportion for no ovarian cyst formation
in group B (n = 10 studies) was 84% (95% CI 70–101),
(I2 = 0.0%, p = 0.885). No ovarian cyst formation was ob-
served in the subgroup of patients with subcutaneous OT
(n = 1 study, weight = 0.85%) (95% CI 70–110). Pooling of
results from 23 studies in group C rendered a summary
proportion of 95% for no ovarian cyst formation (95% CI
85–106) with no significant variation across the studies
(I2 = 0.0%, p = 1). Subgroup meta-analysis between pa-
tients undergoing subcutaneous versus “traditional” OT
revealed no difference in ovarian cyst formation rate ((95%
CI 55–158) versus (95% CI 84–106)). No significant
heterogeneity was observed across the studies for both
subgroups.
Discussion
The main aim of OT is to maintain ovarian function in
premenopausal women treated with RT. It is now estab-
lished as a simple and reliable method with reduced
morbidity [9]. Published data vary with regards to func-
tional outcomes such as ovarian failure, ovarian cysts
and metastases to the transposed ovaries. Our systematic
review of 24 studies confirms and generalizes the con-
cept that OT is associated with a high preservation of
ovarian function, an acceptable rate of ovarian cysts and
a low risk of metastases in the transposed ovaries. To
our knowledge, this is the first systematic review to












Retrospective Women with vaginal (n = 2) and
cervical (n = 7) cancers
Open-lateral OT in patients undergoing radical
surgery followed by pelvic irradiation (n = 9)





Prospective Women with cervical (n = 39)
and vaginal (n = 1) cancers
Open–lateral OT in patients with
RH + lymphadenectomy (n = 22), primary
radiotherapy alone (n = 14) and radiotherapy
following surgery (n = 4)
Ovarian function by FSH, LH levels,
15/22 from surgery only group
were included




Prospective Women with cervical cancer (n = 22) RH with OT of one or both ovaries outside the
pelvis (n = 5) followed by adjuvant radiotherapy
(n = 17), BR only (n = 5) and BR + teletherapy (n = 12)
Ovarian function by FSH, LH, E2 and
progesterone levels, additional analysis of




Retrospective All but 3 patients had early stage
cervical cancer (n = 14)
All but one had bilateral open OT to the
paracolic gutters (n = 14) in addition to RH,
post-operative radiotherapy (n = 8)
Oestrogen deficiency symptoms, metastatic
disease or required reoperation secondary




Retrospective Premenopausal women with cervical
cancer stage IA and IB (n = 84)
Lateral OT in addition to RH (n = 25)
compared to non-OT group (n = 59)
Symptomatic ovarian cysts and symptoms




Retrospective Women with cervical
cancer (n = 44)
Open intraperitoneal OT in a lateral and cranial
direction (n = 44): In 16/44 women, only one ovary could
be preserved and transposed and radiotherapy (n = 6)
Menopausal symptoms, measurement




Retrospective Women with stage 1 cervical cancer (n = 38) Open (sc) lateral OT (n = 38) as part of their initial
operative procedure and post-operative radiotherapy
(n = 14)
Ovarian function by FSH/LH, ovarian preservation
directly related to estimated scattered dose




Retrospective Premenopausal women with early
stage cervical cancer (n = 104)
Open-lateral OT (n = 82) , post-operative
radiotherapy (n = 24), comparison with non-OT
group (n = 22)
Retention of ovarian function, symptomatic




Retrospective Women with stage Ia and Ib
carcinoma of the cervix (n = 48)
RH with OT (n = 48), EBRT (n = 15) and BR (n = 24) Effect on ovarian function 40 (10–72)
Feeney
1995 [28]
Retrospective Women with stage I-IIa cervical
cancer (n = 132)
Lateral OT at the time of RH (n = 132),
post-operative radiotherapy (n = 28)
Menopausal symptoms, FSH levels and adnexal
pathology, Ovarian function is reserved only in





Prospective Women with cervical
cancer (n = 17)
Laparoscopic unilateral OT (n = 17) post-operative
BR (n = 14 ) and EBRT + BR (n = 3)
Evaluation of ovarian function by clinical
and laboratory criteria, 100% ovarian
preservation in patients younger




Retrospective Patients with 1B cervical cancer prior
to radiation therapy (n = 3)
Laparoscopic OT (n = 3) and had intarcavitary
radiation desiring preservation of fertility.
Menstruating regularly after completion of





Retrospective Description of a new technique for OT
(n = 27), women with cervical cancer only
were included (n = 12)
Open (sc) OT ovary (benign = 15,
cancer = 12) and post-operative EBRT (n = 10)
and BR (n = 1)
Cyst formation, symptoms of menopause
with FSH levels measurement
26 (10–44)


















Table 1 Characteristics of studies (Continued)
Morice 1998a
[30]
Women with 27 vaginal cancers, 9 ovarian
dysgerminomas and 1 pelvic sarcoma
Morice 1998b
[31]
Prospective Only 14/ 24 were included as they were
repeated in other paper published by the
same author and 4 non gyanecological
malignancies, 12 clear cell vaginal and
cervical cancers, 1 vaginal adenocarcinoma,
1 dysgerminoma
Laparoscopic OT (n = 14), BR (n = 13)
and EBRT (n = 5)
Clinical and laboratory follow-up tests of




Prospective Women with cervical cancer (n = 107) Laparoscopic bilateral OT to the paracolic
gutters with RH and lymphadenectomy only
(n = 11), with 60 Gy of vaginal BR along with
surgery (n = 59) or surgery, BR and 45
Gy of EBRT (n = 25)
Ovarian function: by clinical symptoms,
FSH, E2 level, 12 patients were lost to




Retrospective Women with cervical cancer (n = 80) Open OT to one or both ovaries at the time
of exploration for RH or staging
lymphadenectomy, postoperative
irradiation (n = 26)
Ovarian function by FSH, report of cyclic
signs and menopausal symptoms, analysis





Retrospective Women with cervical cancer for which
follow up was available (n = 44)
Open OT, comparison of ovarian preservation
between RT and non-RT groups
Ovarian function by FSH, LH, E2, PRL,




Prospective Women with cervical cancer (n = 56)
Regression analysis of risk factors for ovarian
metastases
Open OT during RH only (n = 30),
with pelvic irradiation (n = 26)
Ovarian function by basal bosy temperature,
FSH, E2 and PG, regression analysis of risk




Retrospective Comparison between OT (n = 27)and 2 non-
OT groups (n = 59) for ovarian preservation
Open OT following RH (n = 27) Ovarian function by FSH 65
Pahisa 2008
[36]
Prospective Women with 1b1 cervical cancer (n = 28) Laparoscopic OT with no RT(n = 16),
BR (n = 7) and EBRT + BR (n = 5)
Ovarian function by clinical symptoms and
FSH and E3; follow up available for





Retrospective Women with cervical cancer (n = 15) Bilateral laparoscopic OT to the paracolic
gutters with uterine preservation followed
by pelvic irradiation (n = 15)
Ovarian function by clinical symptoms and FSH 33
Han 2011 [38] Retrospective Women with cervical cancer (n = 29),
comparison with non-OT group
OT in cervical cancer patients (n = 29)
prior to pelvic irradiation
Ovarian function by E2 and FSH, 19/29





Retrospective Women with cervical cancer (n = 53),
39/53 patients were included
Open (n = 19) and laparoscopic (n = 34) OT
to the paracolic gutters with primary
chemoradiotherapy only (n = 3), with RH
and lymphadenectomy (n = 33) followed by
adjuvant RT (n = 23), with lymphadenectomy followed by
primary chemoradiotherapy (n = 17)
Ovarian function by clinical symptoms
and FSH,14/53 patients were lost on
follow up or FSH not available
39.8
sc = Subcutaneous.
NR = Not reported.


















Figure 2 Quality assessment of the observational studies (MINORS criteria).
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mentioned outcomes.
Selection of patients with early cervical and other gy-
naecological cancers who would benefit from OT is
challenging, as difficulty arises to decide which patients
would require postoperative RT prior to the surgical
procedure [40]. To overcome this problem, we examined
3 treatment groups: Group A consisted of those patients
who had surgery only. Patients in group B had post-
operative BR. Group C consisted of patients who had
primarily EBRT following surgery ± BR. OT was the fixed
variable for all groups. In the absence of control groups
for each treatment modality, the approach allowed for
an indirect comparison amongst surgery, BR and EBRT
without the risk of increasing missing data.Figure 3 Ovarian preservation and surgery only group. Forest plot sho
preserved ovarian function following ovarian transposition who had surgerFollowing a comprehensive search strategy, we employed
the MINORS criteria, as indicated for quality assessment of
the included observational non-comparative studies. We
took into account the specific weight of the studies and after
checking for heterogeneity, we employed a random-effects
model to combine the data across studies to control variabil-
ity. However, the majority of studies were of retrospective
design. They were all observational; hence most were not
designed for the specific outcomes examined with the ex-
ception of ovarian function. There was little evidence of
publication bias as shown by the funnel-plot symmetry
(Figure 6). The primary studies did not stratify their results
by confounding factors such as age and follow up and hence,
adjustment for these factors was not possible. Therefore, a
certain degree of clinical heterogeneity should be expected.wing the proportions of women (with confidence intervals) with
y alone.
Figure 4 Ovarian preservation and brachytherapy (BR) ± surgery group. Forest plot showing the proportions of women (with confidence
intervals) with preserved ovarian function following ovarian transposition who had brachytherapy (BR) ± surgery.
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tient’s symptoms and serum FSH levels. Ovarian dose
tolerance depends on volume irradiated, total radiation
dose and the fractionation schedule in addition to pa-
tient’s age at the time of treatment. A fractionated doseFigure 5 Ovarian preservation and external beam radiotherapy (EBRT
proportions of women (with 95% Confidence Intervals) with preserved ova
radiotherapy (EBRT) + surgery ± brachytherapy (BR).exceeding 24 Gy to the ovaries can produce permanent
ovarian ablation [41]. We demonstrated that ovarian
function was highly preserved in those patients who had
no adjuvant RT irrespective of the type of transposition
or the position of transposed ovaries [25]. Only 10% of) + surgery ± brachytherapy (BR) group. Forest plot showing the
rian function following ovarian transposition who had external beam
Figure 6 Funnel plot of the random-effect estimates of the individual studies for ovarian preservation. The vertical line indicates the
random-effects summary estimate (using inverse-variance weighting) while the sloping lines indicate the 95% confidence intervals. Little
heterogeneity was observed.
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etically they should be 5% or less [42]. Notably, those pa-
tients who had BR ± surgery (group B) performed as
good as the surgery only group (group A). However, the
strength of this inference may be reduced by the wider
confidence intervals in this group due to smaller numbersFigure 7 Subgroup meta-analysis for no ovarian cyst formation and s
(with 95% Confidence Intervals) with no ovarian cysts between subgroups
transposition. All patients had surgery alone.of patients. While, the proportions of patients who had BR
with intact uterus in group B is not known, we speculate a
“timing effect” of the OT prior to irradiation as opposed
to simultaneously at surgery. If OT takes place at the time
of an extensive surgery, the risk for vascular compromise
to the ovary from trauma or RH should be higher. Yet, theurgery group alone. Forest plot showing the proportions of women
of those with lateral ovarian transposition versus subcutaneous ovarian
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length of follow up with 7% failing within 3 years and up
to 50% within 5 years [22]. We noted that mean follow up
in group B was shorter compared to group A, which might
be partly responsible for the performance of the BR group.
Notably, we observed that ovarian function was better pre-
served in those patients who have BR only without EBRT,
consistent with the study by Morice et al. [32]. A plausible
speculation for this is that EBRT may be damaging the
vascular supply to the ovary as it loops down the pelvic
brim before ascending again out of the brim to the trans-
posed position. Therefore, if transposing an ovary prior to
EBRT great care should be made to transpose the pedicle
in addition to the ovary.
Further comparison between OT and non-OT cancer
groups is required to assess directly the efficacy of OT
for ovarian function preservation. However, considering
that older women appear more susceptible to permanent
ovarian damage compared to young women, it is expected
that the incidence of ovarian failure following anticancer
treatment ranges between 30-50% [43]. Therefore, al-
though a direct comparison was not possible in the
absence of non-OT cancer groups, we report an apparent
benefit from OT for all treatment groups.
We demonstrated that the risk of ovarian carcinoma
affecting the transposed ovaries is extremely low. Several
risk factors for ovarian involvement have been suggested
[15]. It appears that non-squamous histology carries a
higher risk than the squamous one. Sutton et al. reported
an incidence of 0.5% in squamous cell carcinoma com-
pared to 1.7% in adenocarcinoma [44]. Therefore, ovarian
metastasis in early cervical cancer occurs very rarely [45].
Moreover, the incidence of port site metastasis is <1%
[32], which would explain our results, as the majority of
transpositions were performed laparoscopically.
Risk factors for cyst development include previous sur-
gery, extensive ovarian mobilisation albeit the mechan-
ism is unknown and gynaecological pathology such as
endometriosis or pelvic inflammatory disease [23]. In
that respect, It is not surprising that the incidence of
ovarian cyst formation in the transposed ovaries was
common in the surgery only group (13%). In the sub-
group meta-analysis, the possible advantages of subcuta-
neous transposition such as early detection and easier
diagnosis of ovarian cysts, easy surgical access to remove
ovarian cysts and facilitation of in vitro fertilization [8]
were outweighed by a trend towards higher rate of ovar-
ian cyst formation (43%) possibly due to the more exten-
sive ovarian mobilisation at the time of subcutaneous
transposition [23]. The risk for cyst formation was com-
parable to the BR group. As expected, only 5% of
patients in the EBRT group had ovarian cysts because
of the well-established association between menopausal
status and ovarian cyst formation. Symptomatic cystswere identified by imaging and were treated either
conservatively or surgically. Surgical treatment included
needle puncture, cystectomy or oophorectomy. Conserva-
tive treatment included analgesics, hormonal or expectant
management.
In conclusion, we confirm the efficacy of OT in pa-
tients undergoing radio-surgical treatment of gynaeco-
logical malignancies with high preservation of ovarian
function and negligible risk of metastases to the trans-
posed ovaries despite rather common incidence of ovar-
ian cysts. Surgery alone and post-operative BR groups
performed best for the above outcomes. As quality of
care remains an important issue in cancer care, careful
expansion of patient selection could identify those pre-
menopausal patients who would really benefit from this
rather underutilised procedure.
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